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Abstract
Faithful chromosome segregation during mitosis depends on the Spindle Assembly Checkpoint
(SAC) that monitors kinetochore attachment to the mitotic spindle. Unattached kinetochores
generate mitotic checkpoint proteins complexes (MCCs) that bind and inhibit the Anaphase
Promoting Complex/Cyclosome (APC/C). How the SAC proficiently inhibits the APC/C but still
allows its rapid activation when the last kinetochore attaches to the spindle is important to
understand how cells maintain genomic stability. We show that the APC/C subunit APC15 is
required for the turnover of the APC/C co-activator Cdc20 and release of MCCs during SAC
signalling but not for APC/C activity per se. In the absence of APC15, MCCs and ubiquitylated
Cdc20 remain ‘locked’ onto the APC/C, which prevents the ubiquitylation and degradation of
Cyclin B1 when the SAC is satisfied. We conclude that APC15 mediates the constant turnover of
Cdc20 and MCCs on the APC/C to allow the SAC to respond to the attachment state of
kinetochores.
Introduction
To maintain genomic stability each daughter cell must receive an identical set of sister
chromosomes at mitosis. This is ensured by the SAC, which surveys the attachment state of
kinetochores and prevents the APC/C targeting Cyclin B1 and securin for degradation until
the last kinetochore attaches to the spindle. The APC/C is inactive because its co-activator
Cdc20 is sequestered into MCCs that are initially composed of the Mad2, BubR1 and Bub3
checkpoint proteins 1 that accumulate at unattached kinetochores. How Cdc20 is
incorporated into the MCC and how it is released from the APC/C and MCCs after the SAC
has been satisfied is currently debated.
Contradictory mechanisms have been proposed to release Cdc20 and inactivate MCCs,
including APC/C-dependent proteolysis 2, 3, or the polyubiquitylation but not degradation of
Cdc20 to release Mad2 and the MCC from the APC/C 4. Both mechanisms have been
questioned because a non-ubiquitylatable mutant of Cdc20 dissociates from checkpoint
proteins when the SAC is inactivated and overrides the SAC 5.
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Here, we identify the protein C11orf51 (hereafter referred to as APC15) as a subunit of the
human APC/C required for the release of MCCs from the APC/C and the degradation of
Cdc20. Depleting APC15 increases the amount of Cdc20 and MCCs on the APC/C, which
persist after the SAC is satisfied, thereby delaying progress through mitosis. APC15
depletion, however, does not affect APC/C activity when MCC formation is prevented. We
show that the dissociation of MCCs, and in particular Mad2, proceeds independently of
Cdc20 ubiquitylation; indeed ubiquitylated Cdc20 and Mad2 both accumulate on the APC/C
in the absence of APC15. Nonetheless, APC11 also contributes to the dissociation of MCCs,
indicating that the ubiquitylation of a protein(s) other than Cdc20 may be required. Our data
provide new insights into how the SAC is made responsive to microtubule attachment.
Results
APC15 is a subunit of the human APC/C
We identified C11orf51 in a systematic proteomic analysis of the APC/C purified from
HeLa cell extracts. Human C11orf51 is conserved in animals and has sequence similarity to
the Schizosaccharomyces pombe APC/C subunit Apc15 6 and Saccharomyces cerevisiae
Mnd2 7; therefore, we named it APC15 (Supplementary Fig. S1a online).
To characterise APC15, we used recombinant human APC15 to raise a polyclonal antibody
that recognised a protein of the predicted molecular mass (14.3 kDa) on immunoblots from
HeLa cell extracts whose abundance was reduced after siRNA treatment with APC15-
specific oligonucleotides, and co-migrated with recombinant APC15 (Supplementary Fig.
S1b online). All the detectable APC15 co-precipitated with other APC/C subunits (Fig. 1a)
throughout the cell cycle (Fig. 1b), and co-migrated with them in size-exclusion
chromatography (Fig. 1c). APC15 required APC8 for stability and to be incorporated into
the APC/C (Fig. 1d; Supplementary Fig. S2a, b online), and in vitro binding assays and the
recent structure of S. cerevisiae APC/C indicated that Mnd2 also associated with Apc8 7, 8.
Moreover, MND2͇ and CDC23-1 (APC8) mutants are synthetically lethal 9 and human
APC15 was detected in APC8-GFP immunoprecipitates 10.
APC15 depletion delays anaphase and Cyclin B1 degradation
To elucidate the function of APC15 we used five different siRNAs that reduced the
abundance of APC15 in HeLa and in hTert-immortalised human retinal pigment epithelial
(RPE1) cells (Fig. 2a). We analysed the effect of depleting APC15 on progress through
mitosis in RPE1 cell lines in which the Venus fluorescent protein had been ‘knocked-in’ to
one allele of the Cyclin B1 or Cyclin A2 gene (PC, O. Naschekina, and J.P, in preparation);
therefore, the intensity of the Venus fluorescence was directly correlated with the abundance
of endogenous Cyclin A2 and B1. Depleting APC15 by any of the siRNA treatments
delayed progress from nuclear envelope breakdown (NEBD) to anaphase in cycling cells by
at least a factor of two (Fig. 2b: 22 ± 3 min in control cells; 44 ± 21 to 54 ± 28 min in
APC15-depleted cells, see Supplementary Information Table 1 online for statistical
analyses). This phenotype was caused by the lack of APC15 because siRNA-resistant
APC15 eliminated the delay (Supplementary Fig. S3c online). In APC15-depleted cells
chromosomes aligned at the same time as in controls, but cells subsequently arrested with a
well-formed metaphase plate (Fig. 2c).
Assaying Cyclin B1-Venus fluorescence in single cells 11 revealed that APC15-depleted
cells initiated Cyclin B1 degradation slightly later and degraded it at a slower rate than did
controls (Fig. 2d; Supplementary Fig. S3a, b online), whereas inactivating the APC/C by
depleting APC3 stabilised Cyclin B1 and severely delayed mitosis (Figs 2d, 3b) 12, 13. By
contrast, depleting APC15 did not appear to affect APC/C activity because the kinetics of
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Cyclin A2 degradation, a SAC-independent substrate 14, was largely unchanged, although
degradation was slower shortly before anaphase compared to control cells. The time of this
divergence correlated with the satisfaction of the SAC (marked by an asterisk Fig. 2e), and
maintaining the SAC with dimethylenastron (DMA) also slowed Cyclin A2-Venus
degradation (Fig. 2e). The slow down in Cyclin A2-Venus degradation in APC15-depleted
cells was explained by the prolonged presence of MCCs on the APC/C (see below), which
competed with Cyclin A2 for Cdc20 14.
In agreement with single cell analyses, immunoblots of APC15-depleted HeLa cells
progressing through mitosis showed a delay in Cyclin B1 but not Cyclin A2 degradation,
and also revealed that Cdc20 was stabilised (Supplementary Fig. S2c online).
APC15 functions through the SAC but is not required for APC/C activity
Cdc20 is degraded when the SAC is active 5, 15-17, therefore, the stabilisation of Cdc20 and
Cyclin B1, but not Cyclin A2, indicated that depleting APC15 probably perturbed the
regulation of the APC/C by the SAC. To test this, we assayed APC/C activity in APC15-
depleted cells after abrogating the SAC either by co-depleting Mad2 18, 19, or treating cells
with 0.5 ͮM reversine, an inhibitor of the Mps1 kinase 20. Both treatments eliminated the
metaphase delay (Fig. 3a, b). This indicated that in the absence of the SAC, APC/C activity
was likely to be the same in control and APC15-depleted cells. We confirmed this by
treating control and APC15-depleted cells with reversine, which showed that Cyclin B1 was
degraded with very similar rates in control and APC15-depleted cells (Fig. 3c), and that the
kinetics of Cyclin A2 degradation in control, DMA-treated, and APC15-depleted cells were
identical (Fig. 3d).
To support our conclusion that depleting APC15 did not directly affect APC/C activity, we
sensitised the APC/C by co-depleting APC15 and another APC/C subunit, APC10. Apc10
deletions in S. cerevisiae are viable but APC/C purified from these cells was less processive
in ubiquitylating the B-type cyclin, Clb2 21. To assay APC/C activity independently of the
SAC we used reversine and observed that, as predicted, the depletion of APC10 slightly
reduced the rate of Cyclin B1-Venus degradation, but co-depleting APC15 and APC10 did
not have an additive effect (Supplementary Information Fig. S4a online).
To verify that APC15 did not contribute to APC/C activity in the absence of the SAC, we
assayed interphase APC/C activity in vitro using purified components 22. Control- and
APC15-depleted APC/C showed almost identical activity against Cyclin B1 (Fig. 3e).
We conclude that depleting APC15 does not affect APC/C activity per se but causes a SAC-
dependent delay in both the destruction of Cyclin B1 and the initiation of anaphase.
APC15 depletion increases the association between the APC/C and the MCC
To determine how APC15 influenced APC/C activity through the SAC we analysed APC/C
and SAC complexes in cells depleted of APC15. As a positive control we compared them to
complexes from p31comet–depleted cells. p31comet antagonises the dimerisation of the two
conformations of Mad2 and is required to inactivate the SAC 23-27. In cells treated with
DMA to impose the SAC, depleting APC15 stabilised Cdc20 and caused a three to four fold
increase in the amounts of Mad2 and Bub3, and a two-fold increase in BubR1 and Cdc20,
bound to the APC/C (Fig.4a, Supplementary Information Table 1 online). All these effects
were rescued by expressing a siRNA-resistant APC15 (Supplementary Fig. S4b online).
Depleting p31comet had a smaller effect and influenced mainly the amount of Mad2
precipitating with the APC/C (Fig. 4a). We also analysed Cdc20 immunoprecipitates from
the same extracts to determine the effect on MCCs that were not bound to the APC/C and
found that depleting APC15 or p31comet caused a two to three fold increase in Mad2 and
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Bub3 levels co-precipitating with Cdc20 (Fig. 4b). Size-exclusion chromatography
confirmed that depleting APC15 enriched Mad2 on the APC/C, and enriched both Cdc20
and Mad2 in APC/C-unbound MCCs (control: Cdc20APC/C vs. Cdc20MCC = 2:1; APC15
siRNA: Cdc20APC/C vs. Cdc20MCC = 1.25:1). Consequently, the pool of free Mad2
decreased from 88% in control to 50% in APC15-depleted cells (Fig. 4c, Supplementary
Fig. S5a, b online). Depleting p31comet only increased the amount of Cdc20 and Mad2 in
unbound MCCs (Cdc20APC/C vs. Cdc20MCC = 1:1.75, Fig. 4c, Supplementary Fig. S5c
online).
These experiments indicated that during SAC signalling there was a flux of MCC-Cdc20 on
and off the APC/C that was blocked in the absence of APC15, and that p31comet was
required for the turnover of non-APC/C-bound MCCs. If so, one consequence might be that
during the SAC a population of APC/C could briefly be devoid of MCCs (apo-APC/C 28)
and able to bind free Cdc20 and degrade some Cyclin B1. This could be one explanation for
why some cancer cells ‘slip’ out of mitosis as a consequence of the slow proteolysis of
Cyclin B1 29-31. Interfering with APC15 or p31comet, which should reduce the population of
apo-APC/C, provided some support for this model because it markedly reduced mitotic
slippage in the presence of 5 ͮM taxol (Supplementary Fig. S4c online: t50% slippage in
control cells 258 min, in si-APC15 cells 1094 min, in si-p31comet cells 624 min).
APC15 is required for the release from SAC inhibition
To determine what happens when SAC signalling is turned off we treated cells with the
Aurora B inhibitor ZM447439 32, which inactivates or satisfies the SAC 33. Compared to
control-depleted cells, ZM447439 treatment did not reduce the NEBD to anaphase delay in
APC15-depleted cells (Fig. 5a; Supplementary Information Table 1 online). This indicated
that in the absence of APC15, MCCs might not be released from the APC/C after the SAC
had been satisfied.
To test the requirement for APC15 to dissociate MCCs from the APC/C we released cells
from a DMA-block into fresh medium containing MG132 (to block mitotic exit) and
monitored the dissociation of SAC proteins from the APC/C over time. Whereas MCCs
readily dissociated from the APC/C in control cells, both APC15-and p31comet-depletion
stabilised BubR1, Mad2 and Bub3 on the APC/C (Supplementary Fig. S6a online).
To measure the dissociation of MCC components from the APC/C independently of the
variable time required for kinetochores to attach to microtubules and satisfy the SAC, we
repeated the experiment in the presence of reversine to inactivate the SAC. Again, depleting
APC15 strongly impaired the release of MCCs, whereas p31comet-depletion showed a less
pronounced effect (Fig 5b, Supplementary Fig. S6b online), indicating that APC15 and
p31comet might regulate different aspects of the SAC. Indeed, depleting both APC15 and
p31comet had an additive effect on the delay from NEBD to anaphase (97±25 min,
Supplementary Fig. S7a online). Importantly, APC15 depletion did not affect the transient
interaction of p31comet with the APC/C, excluding the possibility that p31comet acts through
APC15 to release MCCs from the APC/C (Supplementary Fig. S7b, c online).
MCC components had been shown to dissociate from the APC/C purified from SAC-
arrested cells during in vitro ubiquitylation reactions 4 concomitantly with an increase in
Cyclin B1 ubiquitylation (Supplementary Fig. S6c, d online). We confirmed this result and
found that this release also required APC15 because, compared to control-depleted cells,
APC/C purified from APC15-depleted cells retained MCCs and these inhibited the
ubiquitylation of Cyclin B1 (Fig. 5c, d; Supplementary Fig. S6e, f online). Since in vitro
ubiquitylation reactions do not contain the components that generate a SAC signal
(kinetochores), we conclude that the role of APC15 in the release of the MCC is constitutive
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and intrinsic to the APC/C. However, we cannot exclude that in vivo upon satisfaction of the
SAC there is crosstalk between the SAC and the APC/C that might involve APC15.
To provide further evidence that APC15 reduces APC/C activity by retaining MCCs on the
APC/C, and not because APC15 directly contributes to APC/C activity, we purified mitotic
APC/C from control and APC15-depeleted cells that was devoid of MCCs. We synchronised
HeLa cells and added MG132 and reversine shortly before NEBD. APC/C immuno-
precipitates from control and APC15-depleted cells had no detectable Bub3, almost no
Mad2 and only marginal amounts of BubR1, even though APC15 was efficiently depleted
(Supplementary Fig. S7d online). In vitro ubiquitylation reactions showed that the mitotic
APC/C was equally as active when purified from control- or from APC15-depleted cells. By
contrast, APC/C from APC11-depleted cells was markedly less active (Supplementary Fig.
S7e online). We conclude that APC15 is not required for APC/C activity in mitosis.
Cdc20 ubiquitylation is not required to dissociate MCCs from the APC/C
The ubiquitylation of Cdc20 has been proposed to disassemble MCCs by interfering with
Mad2-binding through eliciting a conformational change in Cdc20, or by direct steric
occlusion of the Mad2 binding surface 4. Since APC15 depletion stabilised Cdc20 (Figs 4a,
7a, Supplementary Fig. S2c online,) we analysed whether APC15-depletion prevented
Cdc20 ubiquitylation, which might also explain the elevated amount of Mad2 on the APC/C.
In contrast, we found that in the absence of APC15 both ubiquitylated Cdc20 and Mad2
were enriched on the APC/C (Fig. 6a, b), indicating that the ubiquitylation of Cdc20 did not
disrupt the MCC. This agreed with our previous observation that a non-ubiquitylatable
Cdc20 mutant (in which all the lysines were mutated to arginine) could be released from
APC/C-unbound MCCs when the SAC was satisfied 5. Nevertheless, the mechanism of
Cdc20-release might differ between APC/C-bound and –unbound MCCs 34, 35; therefore, we
sought to determine whether a non-ubiquitylatable Cdc20 could be released from APC/C-
bound complexes.
Our mass spectrometry analysis of the APC/C had identified lysine 490, close to the
carboxyl-terminus of Cdc20, as ubiquitylated in prometaphase (Supplementary Fig. S8a
online), in agreement with a recent mass spectrometry study, which reported that the
neighbouring lysine 485 could also be ubiquitylated 36. Mutating just these two lysines to
arginine completely prevented ubiquitylation and had no effect on the ability of Cdc20 to
bind the APC/C (Fig. 6c, d). Moreover, Cdc20K485/490R dissociated with the other MCC
components from the APC/C with comparable efficiency to wild type Cdc20 (Cdc20WT, Fig
6c, e). Therefore, we conclude that Cdc20 ubiquitylation is not required to dissociate Mad2
and the MCC from the APC/C.
APC11 contributes to the release of MCCs from the APC/C
To test whether the increase of MCCs on the APC/C is specific to APC15 depletion, we
monitored MCC binding to the APC/C during SAC signalling in the absence of several other
APC/C subunits. Depleting APC3 had no effect, whereas depleting APC6 and APC8
strongly reduced MCC binding to the APC/C (Supplementary Fig. S8b online). This result
was expected because we recently showed that APC8 was required to recruit MCC-Cdc20 to
the APC/C 13, and APC8 required APC6 to incorporate into the APC/C (Fig. 1d). To reduce
APC/C activity directly we depleted APC10, which should primarily affect activity in
metaphase 13 and APC11, which should inactivate the APC/C entirely 37, 38. Depleting
APC11, but not APC10, stabilised Cdc20 and Cyclin A during SAC signalling (Fig. 7a).
Depleting APC11 also increased the amount of MCCs on the APC/C when the SAC was
imposed by DMA, though to a lesser extent than APC15 depletion (Fig. 7b, c). When cells
were released from this arrest into fresh medium containing reversine and MG132 fewer
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MCCs dissociated from the APC/C in the absence of APC11 compared to control APC/C
(Fig. 7d, Supplementary Fig. S8c online).
To confirm that APC/C ubiquitylation activity was required for the release of MCCs we
depleted UbcH10, an E2 specifically used by the APC/C 22, 39. Depleting UbcH10 enriched
Mad2 and Bub3 on the APC/C to a similar extent as depleting APC11 but had no effect on
the dissociation of MCCs (Fig. 7c, e; Supplementary Fig. S8e online), As a result, by the end
of the time course the APC/C from UbcH10-depleted cells contained only slightly elevated
amounts of BubR1, Mad2 and Bub3 compared to control cells (Fig. 7e; Supplementary Fig.
S8d online). This was in agreement with our observation that depleting UbcH10 in vivo had
little or no effect on mitosis in cycling cells 40. Thus, although Cdc20 ubiquitylation was
irrelevant to the release of MCCs, the effect of depleting APC11 and UbcH10 indicated that
other proteins might have to be ubiquitylated for MCC turnover on the APC/C.
Discussion
We have identified an APC/C subunit that is primarily required for the turnover of
checkpoint complexes on the APC/C and thus the responsiveness of the SAC. The turnover
of MCCs on the APC/C during SAC signalling continuously generates APC/C devoid of
MCCs and Cdc20 (apoAPC/C 28) that would be available for the rapid activation of the
APC/C when the SAC is satisfied. In the absence of APC15 the MCC remains ‘locked’ onto
the APC/C with ubiquitylated Cdc20, causing MCCs that are not yet bound to the APC/C to
accumulate. Our evidence indicates that p31comet has an important role in the turnover of
these unbound MCCs (Supplementary Fig. S9a, b online).
That the phenotype of APC15-depletion depends on SAC signalling might indicate that
depleting APC15 itself imposes the SAC, or that APC/C activity is compromised and
countered by abrogating the SAC. However, several lines of evidence argue against these
possibilities. It is unlikely that APC15 depletion activates the SAC, because inactivating the
SAC after MCCs have been recruited to the APC/C has no effect on the APC15-dependent
delay in mitosis: only abrogating the SAC before mitosis rescues APC15 depletion. Several
lines of evidence show that depleting APC15 does not compromise APC/C activity: i) the
degradation of Cyclin A is hardly affected in the absence of APC15; ii) the kinetics of
Cyclin B1 destruction is identical to controls in the absence of the SAC; iii) APC15 is not
required for APC/C activity in vitro; iv) Cdc20 ubiquitylation is not affected by APC15
depletion although Cdc20 itself is stabilised, possibly because it cannot be released from the
APC/C to be degraded by the proteasome. By contrast, directly inactivating the APC/C by
depleting APC11 stabilises both Cdc20 and Cyclin A. We note that APC15 deletions in S.
pombe or in S. cerevisiae 6, 7 also show that APC15 is not required for APC/C activity.
How APC15 promotes the release of Mad2 and Bub3 from the APC/C is not clear, but we
can conclude that Cdc20 ubiquitylation is not required because we find ubiquitylated Cdc20
on the APC/C in the absence of APC15; indeed, both Mad2 and ubiquitylated Cdc20
simultaneously accumulate on the APC/C. Furthermore, replacing endogenous Cdc20 with a
non-ubiquitylatable mutant does not affect the release of MCCs from the APC/C. Instead, as
we previously suggested, the ubiquitylation of Cdc20 may be important to target Cdc20 for
proteolysis to maintain the SAC and prevent that increasing amounts of Cdc20 could
eventually overcome the SAC 5, 16. The alternative model, that Cdc20 ubiquitylation drives
the disassembly of the MCC, raises some conceptual problems: the constant generation of
ubiquitylated Cdc20, which would be insensitive to the SAC 4 might immediately activate
the APC/C. To resolve this, Cdc20 has been reported to be deubiquitylated by USP44 41, but
this would generate a futile cycle because this Cdc20 would now be able to activate the
APC/C.
Mansfeld et al. Page 6
Nat Cell Biol. Author manuscript; available in PMC 2012 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Our data indicate that a factor other than Cdc20 might need to be ubiquitylated since
depleting UbcH10 increases the amounts of Mad2 and Bub3 on the APC/C during SAC
signalling and APC11 depletion prevents the release of MCCs from the APC/C. BubR1 is
one attractive candidate because we previously showed that it can be ubiquitylated by the
APC/C in vitro 22, which might be important for progress through mitosis 42. Nonetheless,
although polyubiquitylation appears to be required to release MCCs 4, 34, proteolysis is
not 4, 5, 28, 34.
In contrast to APC11, inactivating the APC/C by depleting APC3 does not increase the
amounts of MCCs on the APC/C, and depleting APC10 slightly decreases MCCs on the
APC/C. This may indicate that APC3 contributes to the stability of the interaction between
the MCC and the APC/C, perhaps through recruiting APC10 13.
A clue to how APC15 regulates Cdc20-MCC binding and release might be gleaned from
studies in S. cerevisiae. While not essential for vegetative divisions, deleting Mnd2 increases
the binding of the meiotic co-activator Ama1 to the APC/C 43. APC15 might, therefore,
modulate Cdc20-MCC binding to prevent it ‘locking’ onto the APC/C. Alternatively,
APC15 might present MCC-Cdc20 as a substrate to the APC/C or recruit a release factor.
APC15 is located in the right position on the APC/C to influence the binding of the MCC
because it seems to interact with APC8, which in turn is needed to bind Cdc20-MCC 13.
Lastly, since the function of APC15 in human cells appears to be primarily linked to the
SAC and its depletion prevents mitotic slippage, APC15 may be a candidate for
chemotherapeutic drugs.
METHODS
Plasmids and cell lines
APC15 was amplified by PCR from a full-length cDNA clone (ORFeome clone 100066673)
obtained from the Mammalian Gene Collection I.M.A.G.E. consortium (Geneservice). For
bacterial expression APC15 was cloned with an amino-terminal TEV (tobacco etch virus)
cleavage site into pet30a (Novagen). Tetracycline-inducible cell lines expressing APC15-
IRES2-mRuby, APC15-3xflag or Cyclin B1-L45A-HA were generated using the FLIP-in
system and a modified pCDNA5/FRT/TO vector (Invitrogen). Cdc20K485/490R was
generated by site directed mutagenesis of Cdc20WT 5. The parental tetracycline-inducible
RPE1 cell line was created by random integration of an FRT site and a Tet repressor
(Invitrogen) gene into RPE1 cells. The tetracyclin-inducible HeLa cell line was a kind gift of
S. Taylor, University of Manchester. For siRNA-rescue experiments HeLa and RPE1 cell
lines were induced with tetracycline (1 ͮg/ml) for 12 hours (si-Cdc20) or 72 hours (si-
APC15) before analysis, respectively. RPE1 Cyclin B1-Venus and Cyclin A2-Venus cell
lines were generated by gene-targeting 46 using a modified protocol (Collin et al.,
manuscript in preparation).
Cell culture and synchronisation
HeLa cells were maintained in Advanced D-MEM supplemented with 10% FCS and
penicillin/streptavidin. RPE1 cells were cultured in F12:DMEM (1:1) media supplemented
with 10% FCS, sodium bicarbonate, glutamate and penicillin/streptavidin. Synchronisation
in different cell cycle phases was always preceded by a standard double thymidine (2.5 mM)
block and release protocol. For G2-phase and G1-phase cells were released into D-MEM for
5 or 18 hours, respectively. Prometaphase cells were collected by mitotic shake off 14 hours
after release into Dimethylanastron (DMA) (10 ͮM), or released for a further two hours into
MG132 (10 ͮM) to obtain a metaphase arrest. To block cells in anaphase, non-degradable
cyclin B1L45A was induced at the final release from a double thymidine block. Cells were
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released for 12 hours into DMA and then released for a further 80 min into fresh D-MEM
and collected by mitotic shake-off. Cycling RPE1 cells were treated with DMA (20 ͮM),
reversine (0.5 ͮM) or ZM447439 (4 ͮM). For mitotic slippage studies cycling RPE1 cells
were arrested in mitosis with taxol (5 ͮM).
RNA interference
RPE1 and HeLa cells were transfected with Lipofectamin RNAiMAX (Invitrogen) and
siRNA oligonucleotides at 50nM for 85 hours prior to analysis by immunoprecipitation or
microscopy if not otherwise stated. For APC10-, APC11-, and UbcH10-depletion, cells were
transfected twice: 12 hours before the start, and after the first release during a double-
thymidine synchronisation protocol. APC6, APC8, APC10 and APC11 were transfected
with a 1:1 mixture of oligo 1 and oligo 2. For experiments characterising the function of
APC15 oligo 4 was used. Control and p31comet oligonucleotides were purchased from
Invitrogen:
GAPDH D-001830-01,
p31comet oligo1 (5ᓉ-UUCUUCGGACUUCUCAUACCACUCC-3ᓉ),
p31comet oligo2 (5ᓉ-CCGCAACUGUGGAGAAGAUUGGUUU-3ᓉ).
APC15 oligonucleotides were purchased from Sigma:
APC15 oligo1 (5ᓉCUGAGACUCUGUGGUUUAA-3ᓉ),
APC15 oligo2 (5ᓉ-GCCAUCAGUCUGCACUUGA-3ᓉ),
APC15 oligo3 (5ᓉ-CGAGAUGAAUGACUACAAU-3ᓉ),
APC15 oligo4 (5ᓉ-GUCUGGUCUAAGUUUCUUU-3ᓉ),
APC15 oligo6 (5;-GGAUCGACCCUGUGUGGAA-3ᓉ).
The remaining oligonucleotides were obtained from Dharmacon:
APC3 (5ᓉ-GGAAAUAGCCGAGAGGUAAUU-3ᓉ),
Mad2 (5ᓉ-GGAAGAGUCGGGACCACAGUU-3ᓉ),
Cdc20 (5ᓉ-CGGAAGACCUGCCGUUACAUU-3ᓉ),
APC11 oligo 1 (5ᓉ-UCUGCAGGAUGGCAUUUAAUU-3ᓉ),
APC11 oligo 2 (5ᓉ-AAGAUUAAGUGCUGGAACGUU-3ᓉ),
APC10 oligo 1 (5ᓉ-GAGCUCCAUUGGUAAAUUUUU-3ᓉ),
APC10 oligo 2 (5ᓉ-GAAAUUGGGUCACAAGCUGUU-3ᓉ),
APC6 oligo1 (5ᓉ-CUAUGGACCUGCAUGGAUAUU-3ᓉ),
APC6 oligo 2 (5ᓉ-CGAGGUAACAGUUGACAAAUU-3ᓉ),
APC8 oligo 1 (5ᓉ-GAAAUUAAAUCCUCGGUAUUU-3ᓉ),
APC8 oligo 2 (5ᓉ-GCAGUUGCCUAUCACAAUAUU-3ᓉ).
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UbcH10 oligo (5ᓉ-GGUAUAAGCUCUCGCUAGATT-3ᓉ).
Microscopy
Before imaging, the culture medium was replaced with Leibovitz’s L-15 medium (Gibco
BRL) supplemented with 10% foetal bovine serum and penicillin/streptomycin. RPE1 and
HeLa cells were imaged on a DeltaVision micrososcope (API, USA) or an ImageXpress
Micro widefield system (Molecular Devices, USA). Images were captured at 3 minutes
intervals and the fluorescence intensities were measured and analysed using ImageJ software
as previously described 11. For presentation noise reduction was applied using the Sigma
filter of the ImageJ software. Statistical analysis was performed using Prism4 software
(Graphpad Software). The data were visualised on scatter dot blots showing the mean.
Protein expression, antibodies and quantitative immunoblotting
Polyclonal antibodies were generated by Moravian Biotechnology (Brno, Slovakia) against
full-length His-TEV-hAPC15 purified from BL21 E. coli using standard techniques. Epitope
tags were removed by TEV cleavage prior to immunization. Expression and purification of
proteins used for in vitro ubiquitylation reactions were performed as previously described 22.
The following antibodies were used at the indicated dilution: APC15 (polyclonal antibody
raised full-length APC15, 1:500), Cdc20 (sc-13162, 1:250; Santa Cruz Biotechnology),
Cdc20 (sc5296, for immunoprecipitations only; Santa Cruz Biotechnology,), Mad2 (Clone
AS55-A12, 1:500; a kind gift of Andrea Musacchio, IFOM, Milan), Mad2 (A300-301A;
1:1000, Bethyl Laboratories), p31comet (Clone E29.19.14, 1:200; a kind gift of Andrea
Musacchio), BubR1 (A300-386A, 1:1000; Bethyl Laboratories), Bub3 (611730, 1:500; BD
Transduction Laboratories), Cyclin B1 (mAb GNS-1, 1:2000; BD Pharmingen), Cyclin A2
(monoclonal antibody raised against a N-terminal peptide, 1:1000), phospho-H3 S10
(14955, 1:1000; Abcam), ͣ-actin (AC-40, 1:1000, Sigma), APC3 (610455, 1:500; BD
Transduction Laboratories), APC3 (clone AF3.1, a kind gift of Tim Hunt, CRUK, London),
APC4 (monoclonal antibody raised against a C-terminal peptide, 1:1000), APC11
(monoclonal antibody raised against a C-terminal peptide, 1:500). APC7 (4171, 1:500;
Abcam), Cdc16 (sc-6395;, Santa Cruz Biotechnology, 1:500), APC10 (1:2000; raised
against full length protein), APC11 (monoclonal antibody raised against a C-terminal
peptide, 1:500), UbcH10 (A-650, Boston Biochem, 1:500). Secondary antibodies: Alexa
Flour 680 rabbit anti-goat (A21088, Invitrogen), IRDye680 donkey anti-mouse
(926-322227, LI-COR), Alexa Fluor 680 goat anti- rabbit (A21076, Invitrogen),
IRDye800CW donkey anti-mouse (926-32212, LI-COR), IRDye800CW donkey anti-rabbit
(926-32213, LI-COR), anti-mouse IgG-peroxidase (A9044, Sigma) were all used at
1:10000. Quantitative immunoblotting was performed on a LI-COR Odyssey CCD scanner
according to the manufacturer’s instructions (LI-COR Biosciences).
Immunoprecipitation and size exclusion chromatography
Cells were lysed for 25 minutes on ice in extraction buffer A (50 mM Tris-HCl pH=8.0, 150
mM NaCl, 0.5 % NP-40, 1 mM dithiothreitol (DTT), Roche complete inhibitor cocktail
tablet, 0.2 ͮM microcystin, 1 mM PMSF) and lysates cleared by centrifugation (15 min,
16.100g). Protein complexes were precipitated with antibodies covalently coupled to
Dynabeads (Invitrogen), washed in extraction buffer and bound proteins eluted by LDS-
sample buffer (Invitrogen). Size-exclusion chromatography was performed on a Superose 6
PC 3.2/30 column (GE Healthcare) as previously described 5 using cells resuspendend in
buffer B (175 mM NaCl, 30 mM Hepes pH 7.8, 2.5 mM MgCl2, 10% glycerol, 1 mM
dithiothreitol (DTT), 0.2 ͮM microcystin, 1 mM PMSF).
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In vitro ubiquitylation assays and in vitro dissociation of checkpoint proteins
In vitro ubiquitylation assays were performed as described previously 22 using APC/C
immobilised on APC4 or APC3 beads. Ubiquitylation reactions contained ubiquitin-
activating enzyme E1, UbcH10, Ube2S, Cdc20, ubiquitin, ATP, ATP regenerating system,
and radio-labelled cyclin B1 (1-86) as a substrate in QPIP buffer (50 mM PIPES at pH 7.5,
100 mM NaCl, 2 mM MgCl2, 10% glycerol, 1 mM DTT and 1 mM EGTA). Mock reactions
were performed in QPIP buffer containing 1 ͮg/ul BSA. Dissociation experiments were
performed without (Supplementary Fig. S6c online, mock reactions) or with unlabelled
substrate (Fig. 5c).
Statistics
Statistical analyses were performed using GraphPad Prism. Significance of data derived
from single cell destruction assays was determined using unpaired, two-tailed Mann-
Whitney tests. Binding to APC/C or Cdc20 immunoprecipitates was analysed by paired,
two-tailed Student’s t tests. The results are summarised in Supplementary Information,
Table 1 online.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
APC15 is a subunit of the human APC/C. (a) APC4 was immunoprecipitated from
asynchronously growing HeLa cells and the co-precipitating APC/C subunits were analysed
by immunoblotting with the indicated antibodies. (b) HeLa cells were synchronised at
different stages of the cell cycle and analysed as in (a). (c) Typical size-exclusion
chromatography of an extract from prometaphase-arrested HeLa cells. The fractions were
analysed by immunoblot (V0=void volume) with the indicated antibodies. (d) Anti-APC4
immunoprecipitations using extracts from prometaphase-arrested HeLa cells that were
treated with 50 nM of the indicated siRNAs for 72h. Note, that depleting APC6 or APC8
causes the APC/C to dissociate into two subcomplexes 13, one of which was precipitated
with anti-APC4 and the other with anti-APC3 (see cartoon and Supplementary Fig. S2b
online). Molecular mass markers on the right of each panel. Results in each panel
representative of at least three experiments.
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Figure 2.
APC15 is an APC/C subunit required for timely entry into anaphase. (a) HeLa (top) or
RPE1 (bottom) cells were treated for 85h with 50 nM of the indicated siRNAs before
analysis by immunoblot. Molecular mass markers on the right. Results representative of
three experiments. (b) The time from NEBD to anaphase of asynchronously growing RPE1-
Cyclin B1-Venus cells, treated as in (a), was determined by fluorescence and phase-contrast
microscopy. Scatter dot blots show the mean (red line) of the indicated number of cells from
three experiments (p<0.0001 versus si-GAPDH for each oligo, Supplementary Table 1). (c)
Montage of representative images showing RPE1-Cyclin B1-Venus/H2B-mRuby expressing
cells treated as in (a) using APC15 oligo 4. NEBD set to 0 min. Scale bar, 10 ͮm. (d and e)
Single-cell destruction assays of asynchronously growing RPE1-Cyclin B1-Venus (d) and
RPE1-Cyclin A2-Venus (e) cells after 85h siRNA-treatment. Images were captured every
three minutes and the total cell fluorescence was measured. Fluorescence intensities were
normalised to NEBD. Error bars indicate s.d. from 25 cells for si-GAPDH and si-APC15
and 15 cells for si-APC3 from three experiments. Only cells that arrested for more than 100
minutes were quantified in si-APC3 experiments. The asterisk (*) indicates the time-point
before the beginning of anaphase in si-GAPDH-treated cells.
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Figure 3.
APC15 depletion causes a SAC-dependent delay in mitosis but does not affect APC/C
activity. (a and b) The timing from NEBD to anaphase of asynchronously growing RPE1-
Cyclin B1-Venus cells treated for 85h with the indicated siRNAs was determined by
microscopy. Si-GAPDH and si-APC15 are identical to Fig. 2b as the data are derived from
the same experiments. DMSO or 0.5 ͮM reversine was added as indicated. Scatter dot blots
show the mean (red line) of the indicated number of cells from three experiments (p<0.0001
for si-APC15 versus si-GAPDH in (a) and (b, DMSO panel), Supplementary Table 1
online). Open circles indicate the minimal time that cells were arrested when NEBD or
anaphase was not observed during the experiment. (c and d) Cells were treated as in Fig 2d,
e but with 0.5 ͮM reversine added to the medium before imaging. Error bars indicate s.d.
from 50 cells for si-GAPDH and si-APC15, ten cells for si-APC3 from three experiments (c)
or 25 cells for si-GAPDH and si-APC15, and 50 cells for si-GAPDH + DMA from two
experiments, respectively (d). (e) Autoradiography of an in vitro ubiquitylation assay using
interphase APC/C purified from GAPDH- and APC15-depleted cells. The APC/C was
immunoprecipitated using anti-APC3 antibodies, activated with Cdh1, and probed for its
ability to ubiquitylate Cyclin B1 (aa 1-86). Molecular mass markers on the right. The
quantification shows Cyclin B1 ubiquitylation normalised to si-GAPDH APC/C (mean ±
s.e.m from three experiments).
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Figure 4.
APC15 is required for the turnover of Mad2, BubR1, Bub3 and Cdc20 on the APC/C during
prometaphase. (a and b) Anti-APC3 (a) and anti-Cdc20 (b) immunoprecipitates from HeLa
cells arrested in prometaphase and treated with the indicated siRNAs for 85h, were analysed
by immunoblotting.
The amounts of MCC proteins that precipitated with APC3 or Cdc20 were analysed by
quantitative immuno-blotting and normalised to si-GAPDH-treatment. Molecular mass
markers on right. Bar charts indicate the mean ± s.e.m. from six experiments. (c) Anti-Mad2
immunoblots of fractions from size exclusion chromatography analyses of HeLa cell
extracts treated as in (a). Molecular mass markers on the right. The complete immunoblot
analyses are shown in the Supplementary Information Fig. S5a-c online. Results
representative of two experiments.
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Figure 5.
APC15 is required for the release of Mad2, BubR1 and Bub3 from the APC/C after the SAC
had been satisfied. (a) Timing from NEBD to anaphase in the presence of 4 ͮM ZM447439
in RPE1-Cyclin B1-Venus cells treated as in Fig 3b. Scatter dot blots show the mean (red
line) of the indicated number of cells from three experiments (p<0.0001 for si-APC15 versus
si-GAPDH, Supplementary Table 1 online). Open circles indicate the minimal time that
cells were arrested when NEBD or anaphase was not observed during the experiment. We
noted that adding 4 ͮM ZM447439 slowed progress from NEBD to anaphase by a factor of
~1.5 independently of siRNA treatment (compare Fig. 5a and Fig. 3a). A similar delay has
been previously reported in RPE-1 cells 44 and might reflect the extended time ZM447439-
treated cells spend in prometaphase 33. (b) HeLa cells were released from a DMA-block into
fresh medium containing 0.5 ͮM reversine and 10 ͮM MG132. Samples were collected at
the indicated time-points and the APC/C immunoprecipitated using anti-APC3 antibodies
before analysis by immunoblotting with the indicated antibodies. Molecular mass markers
on the right. The quantification of three experiments is shown in Supplementary Fig. S6b
online). (c) Autoradiography of in vitro ubiquitylation assays using APC/C purified from si-
GAPDH- and si-APC15-treated HeLa cells arrested in prometaphase. The amounts of SAC
proteins bound to the APC/C were determined by immunoblotting an in vitro ubiquitylation
assay done in parallel. The asterisk (*) denotes His-Cdc20 that binds to the APC/C, the
lower band is endogenous Cdc20. Molecular mass markers on the right. The quantification
of two experiments is shown in Supplementary Fig. S6e online. (d) Quantification of
ubiquitylated Cyclin B1 (1-86) normalised to control reactions from three experiments
(mean ± s.e.m).
Mansfeld et al. Page 17
Nat Cell Biol. Author manuscript; available in PMC 2012 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 6.
Ubiquitylation of Cdc20 is not required to release MCCs from the APC/C. (a) Immuno-blot
analysis of Cdc20 ubiquitylation from the experiments shown in Fig 4a. LC denotes the light
chain of Cdc20 antibodies. Molecular mass markers on the right. (b) Ubiquitylated Cdc20
was analysed by quantitative Western blotting from four experiments shown in Fig. 4a. To
determine the relative amount of ubiquitylated Cdc20 on the APC/C the ratio of Cdc20
modified with one to four ubiquitin molecules (Ub1-4, indicated by asterisks) in si-GAPDH-
versus si-APC15- or si-p31comet treatment was determined and normalised to the ratio of
unmodified Cdc20. The value for si-GAPDH-treated cells was set to 1. Bar charts indicate
the mean ± s.e.m. of four experiments (c). Stable cell lines expressing siRNA-resistant Flag-
Cdc20WT or Flag-Cdc20K485/490R from an inducible promoter were treated with si-Cdc20
oligonucleotides for 72h. The cells were arrested with DMA, and then released into fresh
medium containing 0.5 ͮM reversine and 10 ͮM MG132. Samples were collected at the
indicated time-points and the APC/C immunoprecipitated using anti-APC3 antibodies before
immunoblot analysis with the indicated antibodies. Molecular mass markers on the right. (d)
The amount of MCC components bound to the APC/C during the DMA arrest (t=0) was
determined for Cdc20K485/490R and normalised to Cdc20WT. (e) The amount of MCC
components bound to the APC/C 30 minutes after release from the DMA block was
normalised to time-point zero (t=0). Bar charts indicate the mean ± s.e.m. of three
experiments for (d) and (e).
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Figure 7.
Ubiquitylation contributes to the release of MCCs from the APC/C. (a) Immunoblot analysis
with the indicated antibodies of total cell extracts from DMA-arrested HeLa cells that were
treated with the indicated siRNAs using a double transfection protocol (see Supplementary
Methods online). Molecular mass markers on the right. (b) Immunoblot analysis of anti-
APC4 immunoprecipitates from cell extracts shown in (a) with the indicated antibodies. (c)
Quantification of the amount of APC/C-bound SAC proteins during a DMA-arrest shown in
(b) and (e, t=0) relative to si-GAPDH-treated APC/C. Bar charts indicate the mean ± s.e.m.
of six experiments for (b) and of four experiments for (e). (d) HeLa cells from (b) were
released for 30 min into fresh medium containing 0.5 ͮM reversine and 10 ͮM MG132 and
the APC/C precipitated by APC4 antibodies before immunoblot analysis with the indicated
antibodies. (e) HeLa cells treated with the indicated siRNAs were arrested as in (a, t=0) and
released as in (d, t=30). Anti-APC3 immunoprecipitates from the indicated time points were
analysed with the indicated antibodies. The quantification of MCC binding before the
release is shown in (c). The asterisk denotes the UbcH10 signal derived from the first
immune-detection. Molecular mass markers on the right.
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